M
Mathieu Allez
Researcher at University of Paris
Publications - 43
Citations - 4751
Mathieu Allez is an academic researcher from University of Paris. The author has contributed to research in topics: Ustekinumab & Vedolizumab. The author has an hindex of 12, co-authored 43 publications receiving 4364 citations. Previous affiliations of Mathieu Allez include Sorbonne & Paris Diderot University.
Papers
More filters
Journal ArticleDOI
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche,Axel Dignass,Julián Panés,Laurent Beaugerie,John A. Karagiannis,Mathieu Allez,Thomas Ochsenkühn,Timothy R. Orchard,Gerhard Rogler,Edouard Louis,Limas Kupčinskas,Gerassimos J. Mantzaris,Simon Travis,Eduard F. Stange +13 more
TL;DR: The aim of the Consensus is to promote a European perspective on the management of Crohn's disease and its dilemmas to avoid duplication of effort in the future.
Journal ArticleDOI
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass,James O. Lindsay,Andreas Sturm,Alastair Windsor,Jean-Frederic Colombel,Mathieu Allez,G. D'Haens,André D'Hoore,Gerassimos J. Mantzaris,Gottfried Novacek,Tom Øresland,Walter Reinisch,Miquel Sans,Eduard F. Stange,Severine Vermeire,Simon Travis,Gert Van Assche +16 more
TL;DR: The most widely used index for severe UC remains that of Truelove and Witts3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis (Table 1.3) as mentioned in this paper.
Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management
Axel Dignass,James O. Lindsay,Andreas Sturm,Alastair Windsor,Jean-Frédéric Colombel,Mathieu Allez,G. D'Haens,André D'Hoore,Gerassimos J. Mantzaris,Gottfried Novacek,Tom Øresland,W. Reinisch,Miquel Sans,Eduard F. Stange,Severine Vermeire,Simon Travis,Gert A. Van Assche +16 more
TL;DR: In this article, the authors presented a study of Gastroenterology at the University of Toronto and University of Leuven (Belgium) with the aim of identifying the cause of colorectal cancer.
Journal ArticleDOI
Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease
Laurent Peyrin-Biroulet,Marc Ferrante,Fernando Magro,Simon Campbell,Denis Franchimont,Herma H. Fidder,Hans Strid,Sandro Ardizzone,Gigi Veereman-Wauters,Jean Baptiste Chevaux,Mathieu Allez,Silvio Danese,Andreas Sturm +12 more
TL;DR: Accumulating evidence indicates that mucosal healing may change the natural course of the disease by decreasing the need for surgery and reducing hospitalization rates in both ulcerative colitis and Crohn's disease.
Journal ArticleDOI
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
David Laharie,Arnaud Bourreille,Julien Branche,Mathieu Allez,Yoram Bouhnik,Jérôme Filippi,Frank Zerbib,Guillaume Savoye,Lucine Vuitton,Jacques Moreau,Aurelien Amiot,Jacques Cosnes,Elena Ricart,O. Dewit,Antonio López-Sanromán,Mathurin Fumery,F. Carbonnel,Gilles Bommelaer,Benoit Coffin,Xavier Roblin,G. Van Assche,Maria Esteve,Martti Färkkilä,Javier P. Gisbert,P. Marteau,Stéphane Nahon,M. De Vos,Jérôme Lambert,Jean-Yves Mary,Edouard Louis +29 more
TL;DR: In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment and do not favour one drug over the other.